Read this personal message from Soheil Shams as BioDiscovery announces a new transition to the family of Bionano Genomics.If you have not heard already, I want to share some exciting news with you about BioDiscovery. After 24 years of working independently to create the best software solutions we can for the genomics industry, we have now entered into an agreement to join forces with Bionano Genomics and become a wholly-owned subsidiary of Bionano. I believe this combined company will have a very significant and positive impact on the field of genomics allowing us to continue to offer platform-independent multi-omics solutions to our customers. Over the next several months, we will be updating our flagship NxClinical product to integrate SV data using Bionano's Optical Genome Mapping technology with CNV, AOH, Seq Var, and methylation data. This will provide you with a complete genomics solution, regardless of what platform you are using today or will use in the future, and allow the integration of data across multiple platforms and modalities.
I will be moving into the role of Chief Informatics Officer at Bionano in order to continue along this multi-omics solution path. It's also important to note that the rest of the BioDiscovery team that you have been working with will also continue in their current roles. We are happy to have extra resources in joining Bionano and will also be able to draw on their team of engineers, scientists, and support personnel to help our customers achieve the best answers they can for their patients.
If you have any questions, please feel free to reach out to us.
CEO & Founder, BioDiscovery, Inc.
Please note the following:
The BioDiscovery software tools referenced are designed to assist clinical researchers and are not intended as primary diagnostic tools. It is each lab’s responsibility to use the software in accordance with internal policies as well as in compliance with applicable regulations.